

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Furlow Brenda S.</u> (Last) (First) (Middle) 614 MCKINLEY PL N E (Street) MINNEAPOLIS MN 55413 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [TECH]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below) X SVP - GENERAL COUNSEL
	3. Date of Earliest Transaction (Month/Day/Year) 12/07/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/07/2022		M		800	A	\$31.2625	26,892	D	
Common Stock	12/07/2022		S		800	D	\$82.0063	26,092	D	
Common Stock	12/08/2022		M		7,450	A	\$31.2625	33,542	D	
Common Stock	12/08/2022		S		7,450	D	\$82.1222 ⁽¹⁾	26,092	D	
Common Stock								5,320	I	By Trust #1
Common Stock								5,320	I	By Trust #2

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Options (Right to Buy)	\$31.2625	12/07/2022		M		800		(2)	08/09/2024	Common Stock	800	37,212	D	
Stock Options (Right to Buy)	\$31.2625	12/08/2022		M		7,450		(2)	08/09/2024	Common Stock	7,450	29,762	D	
Stock Options (Right to Buy)	\$44.33							(2)	08/08/2025	Common Stock	66,248	66,248	D	
Stock Options (Right to Buy)	\$47.6025							(2)	08/07/2026	Common Stock	39,872	39,872	D	
Stock Options (Right to Buy)	\$47.6025							(3)	08/07/2026	Common Stock	53,160	53,160	D	
Restricted Stock Units	(4)							(5)	(5)	Common Stock	6,716	6,716	D	
Stock Options (Right to Buy)	\$66.9675							(5)	08/05/2027	Common Stock	29,968	29,968	D	
Stock Options (Right to Buy)	\$66.9675							(6)	08/05/2027	Common Stock	39,960	39,960	D	
Stock Options (Right to Buy)	\$66.9675							(7)	08/05/2027	Common Stock	\$33,300	\$33,300	D	
Stock Options (Right to Buy)	\$66.9675							(8)	08/05/2027	Common Stock	33,300	33,300	D	
Stock Options (Right to Buy)	\$93.11							(9)	08/31/2022 03/01/2028	Common Stock	43,988	43,988	D	
Restricted Stock Units	(4)							(9)	(9)	Common Stock	4,668	4,668	D	
Stock Options (Right to Buy)	\$120.455							(9)	08/06/2028	Common Stock	18,240	18,240	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$120.455							(10)	08/06/2028	Common Stock	24,320		24,320	D	
Stock Options (Right to Buy)	\$94.52							(11)	08/15/2029	Common Stock	24,664		24,664	D	
Restricted Stock Units	(4)							(12)	(12)	Common Stock	7,936		7,936	D	

Explanation of Responses:

- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Fully exercisable.
- Options to purchase 13,292 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 13,288 shares vest on each of 8/7/2022 and 8/7/2023.
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 9,992 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 9,988 shares vest on each of 8/5/2023 and 8/5/2024.
- Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
- Options to purchase 11,100 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
- Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 6,080 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
- Options to purchase 6,168 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 6,164 shares vest on 8/15/2024 and 8/15/2026.
- 2,644 shares vest on each of 8/15/2023 and 8/15/2025, and 2,648 shares vest on 8/15/2024.

Remarks:

On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.

/s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow
pursuant to Power of Attorney
previously filed

12/09/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.